Common Contracts
8 similar Underwriting Agreement contracts by BioScrip, Inc., Esperion Therapeutics, Inc., Global Ship Lease, Inc., others
Esperion Therapeutics, Inc. 32,142,858 Shares of Common Stock (par value $0.001 per share) No Pre-Funded Warrants to Purchase Shares of Common Stock and Warrants to Purchase 32,142,858 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • December 7th, 2021 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
Esperion Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 32,142,858 shares of its common stock, par value $0.001 per share (the “Shares”), and (b) no pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock, as such term is defined herein, at an exercise price of $0.01 per share and (ii) common stock warrants to purchase 32,142,858 shares of Common Stock (the “Common Warrants”). The 32,142,858 Shares to be sold by the Company are called the “Firm Shares” and, collectively with the Pre-Funded Warrants and the Common Warrants, the “Firm Securities.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 4,821,428 Shares (collectively, the “Optional Shares”) and/or Common Warrants to purchase up to an aggregate of 4,821,428 shares of Common Stock (the
GLOBAL SHIP LEASE, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 14th, 2021 • Global Ship Lease, Inc. • Deep sea foreign transportation of freight • New York
Introductory. The shareholders of Global Ship Lease, Inc., a Republic of the Marshall Islands corporation (the “Company”), named in Schedule B (collectively, the “Selling Shareholders”) severally propose to sell to the several underwriters named in Schedule A hereto (the “Underwriters”) an aggregate of 4,500,000 shares of the Company’s Class A Common Shares, par value $0.01 per share (the “Shares”). The 4,500,000 Shares to be sold by the Selling Shareholders are called the “Firm Shares.” In addition, the Selling Shareholders have severally granted to the Underwriters an option to purchase up to an additional 675,000 Shares, with each Selling Shareholder selling up to the amount set forth opposite such Selling Shareholder’s name in Schedule B, as provided in Section 2. The additional 675,000 Shares to be sold by the Selling Shareholders pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional
Manchester United plc 5,000,000 Class A Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • March 15th, 2021 • Manchester United PLC • Services-amusement & recreation services • New York
TG THERAPEUTICS, INC. 4,100,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • March 5th, 2019 • Tg Therapeutics, Inc. • Pharmaceutical preparations • New York
TG Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Cantor Fitzgerald & Co. (“Cantor” or the “Underwriter”) an aggregate of 4,100,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 4,100,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to Cantor an option to purchase up to an additional 615,000 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.”
UR-ENERGY INC. 12,195,122 Common Shares (no par value) and Warrants to Purchase 6,097,561 Common Shares Underwriting AgreementUnderwriting Agreement • September 25th, 2018 • Ur-Energy Inc • Gold and silver ores • New York
Ur-Energy Inc., a corporation continued under the Canada Business Corporations Act (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 12,195,122 of its common shares (the “Firm Shares”), no par value per share (the “Common Shares”), and (ii) 12,195,122 warrants of the Company to purchase an aggregate of 6,097,561 Common Shares (the “Firm Warrants”). In addition, the Company has granted to the Underwriters an option to purchase (i) up to an additional 1,829,268 Common Shares pursuant to such option (the “Option Shares” and together with the Firm Shares, the “Shares”) and/or (ii) 1,829,268 additional warrants to purchase up to an additional 914,634 Common Shares (the “Option Warrants” and together with the Firm Warrants, the “Warrants”). Each Share is being sold together with one Warrant; and each full Warrant is exercisable for one-half Common Share at an exercise price of $1.00 per whole share. The Shares
1,043,479 Shares Iradimed Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • December 23rd, 2015 • Iradimed Corp • Surgical & medical instruments & apparatus • California
4,750,000 Shares Lion Biotechnologies, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2015 • Lion Biotechnologies, Inc. • Biological products, (no disgnostic substances) • New York
Introductory. The stockholders of Lion Biotechnologies, Inc., a Nevada corporation (the “Company”), named in Schedule A (the “Selling Stockholders”) propose to sell to the several underwriters named in Schedule B (the “Underwriters”) an aggregate of 4,750,000 shares of the Company’s common stock, par value $0.000041666 per share (the “Shares”), with each Selling Stockholder selling up to the amount set forth opposite such Selling Stockholder’s name in Schedule A, as provided in Section 2. The 4,750,000 Shares to be sold by the Selling Stockholders are called the “Offered Shares.” Jefferies LLC (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule B, the term “Representative” as used herein shall mean you, as Underwriter, and the term “Underwriters” shall mean either the singular or the plur
6,895,873 Shares BioScrip, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • August 19th, 2013 • BioScrip, Inc. • Retail-drug stores and proprietary stores • New York
